Company / FCF Margin
Celldex Therapeutics, Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-13829.1%
FY2025
5-year range
-13829.1% / -1336.4%
FY2021-FY2025
Trend
-507.9%
vs FY2024
Sector context
#143 of 144
Health Care
What the data says
FCF Margin changed -508% YoY in FY2025, a notable deviation from the 9-year average annual change of -110%.
Based on SEC 10-K filings.
-13829.1% in FY2025 with a 5-year CAGR of -13263.5%.
Declined from -1585.2% to -13829.1% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -9350.5pp
- 5-Year Change
- -13263.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 144This company -13829.1% Sector average -209.0%
▼
-6515.7% below sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 507.9% year-over-year.
- Currently 13620.0pp below the Health Care sector average.
- Peak fcf margin was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -13829.1% | -507.9% |
| FY2024 | -2274.9% | -43.5% |
| FY2023 | -1585.2% | +64.6% |
| FY2022 | -4478.6% | -235.1% |
| FY2021 | -1336.4% | -136.3% |
| FY2020 | -565.6% | +57.1% |
| FY2019 | -1319.5% | +22.7% |
| FY2018 | -1706.3% | +74.3% |
| FY2017 | -6631.0% | -288.6% |
| FY2016 | -1706.3% | +9.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026